Bristol-Myers Squibb Company
Tricyclic rho kinase inhibitors
Last updated:
Abstract:
The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating cardiovascular, smooth muscle, oncologic, neuropathologic, autoimmune, fibrotic, and/or inflammatory disorders using the same. ##STR00001##
Status:
Grant
Type:
Utility
Filling date:
29 Nov 2017
Issue date:
19 May 2020